ClinicalTrials.gg
CompletedNCT00256698FACTUpdated Aug 1, 2012Results posted

Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy

A Phase 3 interventional study of Fulvestrant and Anastrozole in Breast Cancer, sponsored by AstraZeneca. Completed at 85 sites in 12 countries. Open to female participants. Per ClinicalTrials.gov, last updated 2012-08-01.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
514
Allocation
Randomized
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 95 studies testing fulvestrant in Breast Neoplasms — 13 open to participants now, 23 under way, 5 of them phase 3. Fulvestrant · Breast Neoplasms.

Enrollment
14th of 94
514 · median 71
Started
2004
with 9 others
Phase 3
21 of 95
3 open now
Registered
16th of 95
by date
Lead sponsor
18 of 95
AstraZeneca

Among the 95 studies testing fulvestrant in Breast Neoplasms, this one is the 14th largest by enrollment of the 94 interventional ones that give a count, is one of 10 that started in 2004, is one of 21 in phase 3, and was the 16th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

13 of the 95 studies testing fulvestrant in Breast Neoplasms are open now, in 7 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About fulvestrant

Fulvestrant: first FDA approval 2002 (FASLODEX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies testing fulvestrant in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to determine the efficacy of anastrozole monotherapy versus maximal oestrogen blockade with combinated therapy of fulvestrant and anastrozole compared with in treatment of hormone receptor positive women with first relapse of breast cancer.

03

Conditions studied

  • Breast Cancer

Keywords

  • Hormone
  • receptor
  • positive
  • breast
  • cancer
  • first
  • relapse
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed , females, histological or cytological confirmed oestrogene and/or progesterone (PgR) receptor positive breast cancer, local recurrence or

Exclusion criteria

Exclusion Criteria:

  • Previous systemic endocrine therapy for advanced or recurrent disease; prior fulvestrant therapy
  • Premenopausal women
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
514 participants (actual)

Study arms

  • Active comparator
    1

    Anastrozole

    Drug: Anastrozole

  • Experimental
    2

    Anastrozole + Fulvestrant

    Drug: Fulvestrant · Drug: Anastrozole

Interventions

  • intramuscular injection 250 mg loading dose (LD) regimen

    Also known as: Faslodex, ZD9238

  • 1 mg oral tablet

    Also known as: Arimidex, ZD1033

06

What researchers measure

Primary outcomes

  1. Time to Progression (TTP)

    RECIST (Response Evaluation Criteria in Solid Tumours) assessments carried out every 8 weeks from randomisation until data cut-off on 30th April 2009. TTP, time in months to worsen 'progression' according to RECIST criteria. (RECIST is a set of published rules that define when cancer patients improve "respond", stay the same "stable"or worsen "progression" during treatments.

    Time frame: RECIST assessments carried out every 8 weeks from randomisation until data cut-off on 30th April 2009

Secondary outcomes

  1. Percentage of Evaluable Participants With Objective Response Rate (ORR)

    No. of patients who were objective responders over the no. of patients evaluable for response x100. An objective responder = a patient whose best response is either CR (disappearance of all lesions) or PR (\>= 30% shrinkage in the sum of the longest diamemeters of the measurable lesions + no new lesions + no progression of non-measurable lesions)

    Time frame: RECIST tumour assessments carried out every 8 weeks from randomisation until data cut-off on 30th April 2009

  2. Percentage of Clinical Benefit Rate (CBR) Responders

    No. of patients who were clinical benefit responders over the no. of randomised patients x100. A clinical benefit responder = a patient whose best response is CR, PR or SD\>=24 weeks (where a best response of SD = no new lesions and for existing lesions; neither suffient shrinkage to count as PR nor sufficient growth to count as progression)

    Time frame: RECIST tumour assessments carried out every 8 weeks from randomisation until data cut-off on 30th April 2009

  3. Duration of Response (DoR)

    Median time from randomisation until objective progression or death (in the absence of objective progression), measured only in those patients who are objective responders

    Time frame: RECIST tumour assessments carried out every 8 weeks from randomisation until data cut-off on 30th April 2009

  4. Duration of Clinical Benefit (DoCB)

    Median time from randomisation until objective progression or death (in the absence of objective progression), measured only in those patients who are clinical benefit responders

    Time frame: RECIST tumour assessments carried out every 8 weeks from randomisation until data cut-off on 30th April 2009

  5. Time to Treatment Failure (TTF)

    Time from randomisation until the date of discontinuation of randomised treatment for any reason

    Time frame: From randomisation until data cut-off on 30th April 2009

  6. Overall Survival (OS)

    Overall survival is equivalent to time to death. Time from randomisation until the date of death

    Time frame: All deaths occurring between randomisation and data cut-off on 30th April 2009 are included.

07

Results

Posted Feb 9, 2011

Participant flow

258 patients were randomised to Fulvestrant + Anastrozole and 256 patients were randomised to Anastrozole. In each treatment group, there were 2 patients who did not receive any trial therapy and so have been excluded from the safety summaries.

Participant flow — Overall Study
MilestoneFulvestrant + AnastrozoleAnastrozole
Started258256
Completed9184
Not completed167172
Withdrew: Withdrawal by subject77
Withdrew: Adverse event136
Withdrew: Protocol violation65
Withdrew: Lost to follow-up13
Withdrew: Disease progression97105
Withdrew: Still ongoing at data cut-off4146
Withdrew: Withdrawn due to osteoporosis10
Withdrew: Prematurely discontinued10

Outcome measures

PrimaryTime to Progression (TTP)

RECIST (Response Evaluation Criteria in Solid Tumours) assessments carried out every 8 weeks from randomisation until data cut-off on 30th April 2009. TTP, time in months to worsen 'progression' according to RECIST criteria. (RECIST is a set of published rules that define when cancer patients improve "respond", stay the same "stable"or worsen "progression" during treatments.

Time frame:
RECIST assessments carried out every 8 weeks from randomisation until data cut-off on 30th April 2009
Reported as:
Median · months
Time to Progression (TTP)
monthsFulvestrant + AnastrozoleAnastrozole
Time to Progression (TTP)10.8 (0 to 49.31)10.2 (0 to 54.34)
SecondaryPercentage of Evaluable Participants With Objective Response Rate (ORR)

No. of patients who were objective responders over the no. of patients evaluable for response x100. An objective responder = a patient whose best response is either CR (disappearance of all lesions) or PR (\>= 30% shrinkage in the sum of the longest diamemeters of the measurable lesions + no new lesions + no progression of non-measurable lesions)

Time frame:
RECIST tumour assessments carried out every 8 weeks from randomisation until data cut-off on 30th April 2009
Reported as:
Number · Percentage of evaluable participants
Percentage of Evaluable Participants With Objective Response Rate (ORR)
Percentage of evaluable participantsFulvestrant + AnastrozoleAnastrozole
Percentage of Evaluable Participants With Objective Response Rate (ORR)31.833.6
SecondaryPercentage of Clinical Benefit Rate (CBR) Responders

No. of patients who were clinical benefit responders over the no. of randomised patients x100. A clinical benefit responder = a patient whose best response is CR, PR or SD\>=24 weeks (where a best response of SD = no new lesions and for existing lesions; neither suffient shrinkage to count as PR nor sufficient growth to count as progression)

Time frame:
RECIST tumour assessments carried out every 8 weeks from randomisation until data cut-off on 30th April 2009
Reported as:
Number · Percentage of participants
Percentage of Clinical Benefit Rate (CBR) Responders
Percentage of participantsFulvestrant + AnastrozoleAnastrozole
Percentage of Clinical Benefit Rate (CBR) Responders55.055.1
SecondaryDuration of Response (DoR)

Median time from randomisation until objective progression or death (in the absence of objective progression), measured only in those patients who are objective responders

Time frame:
RECIST tumour assessments carried out every 8 weeks from randomisation until data cut-off on 30th April 2009
Reported as:
Median · months
Duration of Response (DoR)
monthsFulvestrant + AnastrozoleAnastrozole
Duration of Response (DoR)22.3 (5.55 to 46.95)18.2 (7.20 to 49.77)
SecondaryDuration of Clinical Benefit (DoCB)

Median time from randomisation until objective progression or death (in the absence of objective progression), measured only in those patients who are clinical benefit responders

Time frame:
RECIST tumour assessments carried out every 8 weeks from randomisation until data cut-off on 30th April 2009
Reported as:
Median · months
Duration of Clinical Benefit (DoCB)
monthsFulvestrant + AnastrozoleAnastrozole
Duration of Clinical Benefit (DoCB)18.5 (1.64 to 46.95)18.1 (5.19 to 54.34)
SecondaryTime to Treatment Failure (TTF)

Time from randomisation until the date of discontinuation of randomised treatment for any reason

Time frame:
From randomisation until data cut-off on 30th April 2009
Reported as:
Median · months
Time to Treatment Failure (TTF)
monthsFulvestrant + AnastrozoleAnastrozole
Time to Treatment Failure (TTF)12.4 (0 to 46.95)11.4 (0 to 54.34)
SecondaryOverall Survival (OS)

Overall survival is equivalent to time to death. Time from randomisation until the date of death

Time frame:
All deaths occurring between randomisation and data cut-off on 30th April 2009 are included.
Reported as:
Median · months
Overall Survival (OS)
monthsFulvestrant + AnastrozoleAnastrozole
Overall Survival (OS)37.8 (0.07 to 61.86)38.2 (0.13 to 60.39)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fulvestrant + Anastrozole—40/256 (15.6%)161/256 (62.9%)
Anastrozole—45/254 (17.7%)178/254 (70.1%)
Most frequent serious events
Showing 10 of 89
Most frequent serious events
EventFulvestrant + AnastrozoleAnastrozole
General Physical Health DeteriorationGeneral disorders0/2563/254
Cardiac FailureCardiac disorders3/2561/254
PneumoniaInfections and infestations3/2562/254
DyspnoeaRespiratory, thoracic and mediastinal disorders3/2562/254
Pleural EffusionRespiratory, thoracic and mediastinal disorders3/2560/254
Pericardial EffusionCardiac disorders0/2562/254
VertigoEar and labyrinth disorders0/2562/254
NauseaGastrointestinal disorders2/2562/254
Chest PainGeneral disorders1/2562/254
PainGeneral disorders0/2562/254
Most frequent other events
Showing 10 of 12
Most frequent other events
EventFulvestrant + AnastrozoleAnastrozole
FatigueGeneral disorders27/25633/254
ArthralgiaMusculoskeletal and connective tissue disorders30/25627/254
NauseaGastrointestinal disorders23/25627/254
Hot flushVascular disorders21/25619/254
Musculoskeletal painMusculoskeletal and connective tissue disorders8/25620/254
Back painMusculoskeletal and connective tissue disorders11/25615/254
ConstipationGastrointestinal disorders15/25612/254
DiarrhoeaGastrointestinal disorders15/25613/254
Urinary tract infectionInfections and infestations14/2568/254
CoughRespiratory, thoracic and mediastinal disorders10/25613/254

Baseline characteristics

Age Continuous
Age Continuous(Years)Fulvestrant + AnastrozoleAnastrozoleTotal
Mean65.2 ± 9.663.4 ± 10.364.3 ± 10.0
Sex: Female, Male
Sex: Female, Male(Participants)Fulvestrant + AnastrozoleAnastrozoleTotal
Female258256514
Male000
08

Study locations

85 sites
  • Research Site
    Brampton, Canada
  • Research Site
    Halifax, Canada
  • Research Site
    Kingston, Canada
  • Research Site
    Ontario, Canada
  • Research Site
    Toronto, Canada
  • Research Site
    San Jose, Costa Rica
  • Research Site
    Hameenlinna, Finland
  • Research Site
    Turku, Finland
  • Research Site
    Avignon, France
  • Research Site
    Caen, France
  • Research Site
    Creteil, France
  • Research Site
    Grenoble, France
  • Research Site
    La Chaussee Saint Victor, France
  • Research Site
    Perigueux, France
  • Research Site
    Perpignan, France
  • Research Site
    Saint Cyr Sur Louire, France
  • Research Site
    Toulouse, France
  • Research Site
    Augsburg, Germany
  • Research Site
    Dusseldorf, Germany
  • Research Site
    Erlangen, Germany
  • Research Site
    Frankfurt, Germany
  • Research Site
    Gifhorn, Germany
  • Research Site
    Grosshadern, Germany
  • Research Site
    Halle, Germany
  • Research Site
    Hamburg, Germany
  • Research Site
    Hannover, Germany
  • Research Site
    Heidelberg, Germany
  • Research Site
    Ingolstadt, Germany
  • Research Site
    Kassel, Germany
  • Research Site
    Kiel, Germany
  • Research Site
    Koln, Germany
  • Research Site
    Leipzig, Germany
  • Research Site
    Leverkusen, Germany
  • Research Site
    Magdeburg, Germany
  • Research Site
    Mannheim, Germany
  • Research Site
    Marburg, Germany
  • Research Site
    Munchen, Germany
  • Research Site
    Rostock, Germany
  • Research Site
    Trier, Germany
  • Research Site
    Ulm, Germany
  • Research Site
    Ziwicken, Germany
  • Research Site
    Guatemala, Guatemala
  • Research Site
    Reykjavik, Iceland
  • Research Site
    Como, Italy
  • Research Site
    Fabriano, Italy
  • Research Site
    Ferrara, Italy
  • Research Site
    Firenze, Italy
  • Research Site
    Lugo, Italy
  • Research Site
    Milano, Italy
  • Research Site
    Taormina, Italy
  • Research Site
    Treviglio, Italy
  • Research Site
    Vicenza, Italy
  • Research Site
    Drammen, Norway
  • Research Site
    Ilesund, Norway
  • Research Site
    Oslo, Norway
  • Research Site
    Porsgrunn, Norway
  • Research Site
    Stavanger, Norway
  • Research Site
    Troms, Norway
  • Research Site
    Trondheim, Norway
  • Research Site
    Cascais, Portugal
  • Research Site
    Coimbra, Portugal
  • Research Site
    Lisboa, Portugal
  • Research Site
    Santa Maria da Feira, Portugal
  • Research Site
    Halmstad, Sweden
  • Research Site
    Helsingborg, Sweden
  • Research Site
    Kalmar, Sweden
  • Research Site
    Karlskrona, Sweden
  • Research Site
    Kristianstad, Sweden
  • Research Site
    Link'ping, Sweden
  • Research Site
    M'lndal, Sweden
  • Research Site
    Malm, Sweden
  • Research Site
    Norrk'ping, Sweden
  • Research Site
    Skelleftea, Sweden
  • Research Site
    Skovde, Sweden
  • Research Site
    Stockholm, Sweden
  • Research Site
    Sunderbyn, Sweden
  • Research Site
    Sundsvall, Sweden
  • Research Site
    Umea, Sweden
  • Research Site
    V'rnamo, Sweden
  • Research Site
    V'stervik, Sweden
  • Research Site
    Varberg, Sweden
  • Research Site
    Ankara, Turkey
  • Research Site
    Edirne, Turkey
  • Research Site
    Gaziantep, Turkey
  • Research Site
    Istanbul, Turkey
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2004, a primary completion of Apr 2009 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2011, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2005
First posted
Nov 22, 2005
Start
Jan 2004
Primary completionActual
Apr 2009
CompletionActual
Feb 2012
Results first posted
Feb 9, 2011
Last update
Aug 1, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00256698
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 22, 2005
Start date
Jan 2004
Primary completion
Apr 2009
Completion
Feb 2012
Results posted
Feb 9, 2011
Last update
Aug 1, 2012

Study contacts

Roger Henriksson, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fulvestrant

Start the discussion